Arbutus Biopharma Corporation

Equities

ABUS

CA03879J1003

Pharmaceuticals

Real-time Estimate Cboe BZX 10:04:32 2024-03-28 am EDT 5-day change 1st Jan Change
2.575 USD -0.96% Intraday chart for Arbutus Biopharma Corporation +1.37% +3.40%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Arbutus Biopharma Corporation Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:05 PM
HC Wainwright Trims Price Target on Arbutus Biopharma to $5 From $6, Keeps Buy Rating MT
Transcript : Arbutus Biopharma Corporation, Q4 2023 Earnings Call, Feb 29, 2024
Arbutus Biopharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Arbutus Biopharma, Inc. Announces Clinical Development Milestones to Advance Its HBV Pipeline CI
Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD CI
Arbutus Biopharma Posts Q3 Net Loss, Lower Revenue; CEO to Retire, 24% Research Staff Cut MT
Transcript : Arbutus Biopharma Corporation, Q3 2023 Earnings Call, Nov 07, 2023
Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q3 Revenue $4.7M, vs. Street Est of $4.7M MT
Arbutus Biopharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Arbutus Biopharma Corporation Announces CEO Changes CI
Arbutus Biopharma Corporation Announces President Changes CI
JMP Securities Adjusts Arbutus Biopharma Price Target to $4 From $6, Maintains Market Outperform Rating MT
Arbutus Biopharma Discontinues Coronavirus, Oral RNA Destabilizer Programs, Focuses on Hepatitis B Virus Treatment Assets MT
Arbutus Biopharma Corporation Announces Pipeline Updates and Dosing of First Subject in Phase 1a/1b Clinical Trial with AB-101 CI
Transcript : Arbutus Biopharma Corporation, Q2 2023 Earnings Call, Aug 03, 2023
Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Reports Q2 Revenue $4.7M, vs. Street Est of $6.2M MT
Arbutus Biopharma Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Arbutus Biopharma Corporation Announces the Appointment of Melissa V. Rewolinski to Its Board of Directors CI
Arbutus Biopharma Promotes Dr. Karen Sims to Chief Medical Officer, Hires Christopher Naftzger as Chief Compliance Officer MT
Arbutus Biopharma Corporation Appoints Two New Executives CI
Arbutus' Phase 2a Trial Shows AB-729 Plus Pegylated Interferon Alfa-2a Well Tolerated in Chronic Hepatitis B Virus Patients MT
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2A Triple Combination Clinical Trial That Includes A Pd-1 Monoclonal Antibody CI
Arbutus Presents Preliminary Ab-729 and Pegylated Interferon Alfa-2A Combination Data At the Easl Congress 2023 CI
Arbutus Biopharma Corporation to Present AB-729 and AB-836 Data at EASL Congress 2023 CI
Chart Arbutus Biopharma Corporation
More charts
Arbutus Biopharma Corporation is a clinical-stage, biopharmaceutical company. The Company is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company's focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, an oral capsid inhibitor, an oral programmed death-ligand-1 (PD-L1) inhibitor, and an oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The Company is also having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses, including SARS-CoV-2.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.533 CAD
Average target price
5.957 CAD
Spread / Average Target
+68.58%
Consensus
  1. Stock
  2. Equities
  3. Stock Arbutus Biopharma Corporation - Nasdaq
  4. News Arbutus Biopharma Corporation
  5. Arbutus Biopharma Says it Secures US Patent for Hepatitis B Drug AB-729